The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-o...
We've found 4 total result s for "Triple Negative Breast Neoplasms".
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indicati...
Age: 18 years - 66+
Gender: All
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with ad...
- Neoplasms
- Breast Neoplasms
- Lung Neoplasms
- Ovarian Neoplasms
- Urinary Bladder Neoplasms
- Triple Negative Breast Neoplasms
Age: 18 years - 66+
Gender: All
Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER-2 non-amplification. Women with TNBC tend to be younger, African American, and ...
Age: 18 years - 66+
Gender: Female